This is the second accelerated approval the FDA has granted to Bristol Myers Squibb’s chimeric antigen receptor T-cell ...

FDA has given accelerated approval for lisocabtagene maraleucel (liso-cel; Breyanzi) for patients with relapsed or refractory ...

Forced labor, he declared, was “the only way to civilize and uplift these indolent and corrupt peoples.”) As with many colonial conquests, the resources that first loomed large for the ...

Stephens started coverage of Blueprint Medicines (NASDAQ:BPMC) with a buy rating and a place on its best idea list. The ...

PRESS RELEASEAB SCIENCE ANNOUNCES ISSUANCE OF A EUROPEAN PATENT FOR MASITINIB IN THE TREATMENT OF SEVERE MASTOCYTOSIS WITH PROTECTION UNTIL ...

Hepatocellular carcinoma screening was associated with earlier detection and improved survival, even after accounting for ...

If the student-led protests achieve nothing politically in the U.S., they have at least given hope to the hundreds of ...

† 95% CI: 65–83%. CR: Complete response; ORR: Overall response rate (CR plus UCR plus PR); PD: Progressive disease; PR: Partial response; SD: Stable disease; UCR ...

The FDA is looking at five big decision deadlines in the coming three weeks, including two for a CAR-T therapy and another ...

Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval ...

HAMPTON ROADS, Va. — Hematologist and Oncologist Dr. Pankit Vachhani and Suki Tipp, a woman living with Indolent Systemic Mastocytosis, join Coast Live to discuss the debilitating disease, and a ...

Harvard’s endowment is currently $50.7 billion. That means that the first year, the state would extract about $1.25 billion ...